Chengdu Zenitar Biomedical Technology

Small-molecule pharma (private)

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
HDACSmall molecule
Multiple MyelomaDiffuse Large B-Cell Lymphoma
Phase 2
JAKSmall molecule
Atopic Dermatitis

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Purinostat MesylatePhase 2Diffuse Large B Cell Lymphoma,DLBCL
Est. primary completion 2026-12-30 · NCT05563844 · CT.gov ↗
What to watch
2027 (1)
December 2027 (1)
ZL-82Phase 2Atopic Dermatitis
Est. primary completion 2027-12-30 · NCT07193589 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Purinostat MesylatePhase 3Recurrent and Refractory Diffuse Large B-cell Lymphoma
Est. primary completion 2029-06-30 · NCT07011056 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.